Cytotoxicity News and Research

RSS

Gramicidin-Based Fluorescence Assay can help predict drug toxicity

Sometimes, toxic side effects aren't discovered until fairly late in the drug development process, when substantial amounts of time and money have already been invested in clinical trials.

9 Feb 2015

Study: Stem cells derived from human female amnion have anti-inflammatory effects

Stem cells derived from human amnion have for some time been considered promising for cell therapies because of their ease of access, ability to differentiate, and absence of ethical issues.

17 Jan 2015

Chaetocin synergistic with TKIs against CML cells

Chaetocin, a mycotoxin that increases oxidative stress, can complement the activity of tyrosine kinase inhibitors in chronic myeloid leukaemia by overcoming innate resistance mediated by secreted bone marrow stromal cytokines and growth factors, researchers report.

14 Nov 2014

Scientists identify potent inhibitors to combat common obesity gene

Individuals who are genetically predisposed to obesity may soon have a therapeutic solution to combat their condition. A research team led by scientists from the National University of Singapore (NUS) has identified several potent inhibitors that selectively target FTO, the common fat mass and obesity-associated gene.

21 Oct 2014

Ohio State researchers develop novel anticancer peptide vaccines and inhibitors

Researchers have developed two new anticancer peptide vaccines and two peptide inhibitors as part of a larger peptide immunotherapy effort at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

25 Sep 2014

Electrically insulative epoxy system from Master Bond meets USP Class VI and ISO 10993-5 specifications

With biocompatibility and cytotoxicity certifications, Master Bond EP21AOLV-2Med is often selected for bonding, sealing, coating and encapsulation applications in the medical device industry.

From Master Bond Inc. 18 Sep 2014

Vaccine boosts advanced NSCLC patient survival

Investigation of a vaccine targeting a glycoside present in non-small-cell lung cancer has demonstrated efficacy as a switch therapy for patients with stable, advanced disease after chemotherapy.

28 Aug 2014

Seven physicians receive ASTRO grants to advance radiation oncology research

The American Society for Radiation Oncology has selected seven leading physicians to receive a total of $675,000 in awards and grants to advance radiation oncology research. The ASTRO Junior Faculty Career Research Training Award, the ASTRO Residents/Fellows in Radiation Oncology Research Seed Grant and the ASTRO/Radiation Oncology Institute Comparative Effectiveness Research Award will fund studies in radiation and cancer biology, radiation physics, translational research, outcomes/health services research and comparative effectiveness research within radiation oncology.

12 Aug 2014

New way to combat bacterial biofilm formation with titanium encrusted with gold nanoparticles

Bacteria love to colonize surfaces inside your body, but they have a hard time getting past your rugged, salty skin.

1 Jul 2014

Novel bone implants can keep germs at bay

Hospital germs can be fatal, since they are resistant to antibiotics. As a result, alternative methods of defense against bacteria are in demand. Fortunately, a German-French research team has been able to develop bone implants that keep the germs at bay.

11 Jun 2014

DNA-binding fluorescent dyes evaluate cytotoxicity in real-time during screening

High throughput screening of compounds in live cells is a powerful approach for discovering new drugs, but the potential for cell toxicity must be considered.

31 May 2014

MedImmune to present Phase IIb asthma data on benralizumab and tralokinumab at ATS conference

AstraZeneca today announced that MedImmune, its global biologics research and development arm, will present Phase IIb data on two novel investigational molecules – benralizumab and tralokinumab – at the upcoming American Thoracic Society 2014 International Conference being held in San Diego, California, 16-21 May.

14 May 2014

Angelica sinensis polysaccharides alleviate neuronal cell injury caused by oxidative stress

According to traditional Chinese medicine, the roles of Angelica sinensis correlate with tonifying the blood and promoting its circulation. Recent studies have shown that extracts of Angelica sinensis have antioxidative and neuroprotective effects.

10 Apr 2014

Study provides insight into the mechanisms underlying diabetic peripheral neuropathy

Iron overload can lead to cytotoxicity, and it is a risk factor for diabetic peripheral neuropathy. However, the underlying mechanism remains unclear.

13 Mar 2014

Blocking mechanisms for DNA repair may help to potentiate chemotherapy, says study

Chemotherapies are cancer treatments that work by inducing lesions in the DNA of tumour cells in order to inhibit their proliferation. However, the body naturally tries to repair these lesions, and thus reduces the efficacy of chemotherapy.

24 Feb 2014

arGEN-X reports that Phase Ib cancer study with ARGX-110 antibody meets translational development goals

arGEN-X announces that the dose-escalation part of a Phase Ib study with its lead antibody ARGX-110 has met its translational development goals: all pre-specified biological activity measures (e.g. target engagement, effector functions, immune-modulation) were met.

17 Dec 2013

Allied Healthcare Group commences first shipment of CardioCel into Europe

Allied Healthcare Group today announces it has commenced shipment of CardioCel into Europe after the Company received its first orders for the product from outside of Australia.

8 Nov 2013

arGEN-X announces CTA filing of Phase Ib cancer study with ARGX-111

arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces today the CTA filing of a first-in-man Phase Ib cancer study with ARGX-111, its second proprietary SIMPLE Antibody product to enter the clinic this year.

17 Sep 2013

Study reveals role of cadherin receptor BT-R3 in killing action of Cry4B mosquito toxin

Researchers at The University of Texas at Dallas (UTD), led by Dr. Lee Bulla, have demonstrated for the first time the selective cytotoxicity of Bacillus thuringiensis subsp. israelensis Cry4B toxin is mediated by BT-R3.

27 Aug 2013

Combination of anti-nausea drug and turmeric spice target cancer cells

In a laboratory, preclinical study recently published by the journal Organic & Biomolecular Chemistry, Virginia Commonwealth University Massey Cancer Center researchers combined structural features from anti-nausea drug thalidomide with common kitchen spice turmeric to create hybrid molecules that effectively kill multiple myeloma cells.

20 Aug 2013